Dr. Amy Kruse

Dr. Amy Kruse is the General Partner and Chief Investment Officer of Satori Neuro, a stage-agnostic fund focused on mental health, neurotechnology, and human flourishing.  Amy leverages her decades of experience as a neuroscientist, her prior roles as an operator and a government program manager, and her network of key relationships to discover transformational companies addressing the largest mental health, brain health, and wellness challenges and opportunities.

Prior to leading Satori Neuro, Amy was a General Partner at Prime Movers Lab, where she led the fund’s life sciences investments in human augmentation and longevity.  She previously served as the Chief Scientific Officer of Optios, an applied neuroscience research organization that translates cutting-edge neuroscience discoveries into practical tools to enhance the human experience. 

Her early career was spent in the defense industry, culminating in her role as Vice President and Chief Technology Officer of Cubic Global Defense, where she oversaw the company’s research and development (R&D) programs. Amy joined Cubic through the acquisition of Intific, a small business focused on novel game-based solutions for the DoD and Intelligence Community. Amy served as a government civilian program manager at the Defense Advanced Research Projects Agency (DARPA), where she created and oversaw the Agency’s first performance-oriented neuroscience programs.  Her efforts at DARPA generated scientific breakthroughs in areas that include augmented cognition, accelerated learning, optimized imagery analysis, team neurodynamics, and neuromodulation. 
 

Amy earned a Bachelor of Science in Cell and Structural Biology and a PhD in Neuroscience from the University of Illinois Urbana-Champaign, where she was awarded a National Science Foundation Graduate Fellowship.